Runrun Zhang

Dr. Runrun Zhang


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2024 in Medicine
Verified
Journal Article
Open access
XYXinyi Mm Yao
Xinyi Mm Yao
RZRunrun Zhang
Runrun Zhang
XWXinchang Wang
Xinchang Wang
This study aimed to assess the causal relationship between GM and RA (seropositive RA and seronegative RA). A two-sample Mendelian randomization (MR) analysis was performed to assess the causality of GM on seropositive RA and seronegative RA. GM’s genome-wide association study (GWAS) was used as the exposure, whereas the GWAS datasets of seropositive RA and seronegative RA were the outcomes. The primary analysis approach was used as inverse-variance weighted (IVW), followed by 3 additional MR methods (MR-Egger, weighted median, and weighted mode). Cochran’s Q test was used to identify heterogeneity. The MR-Egger intercept test and leave-one-out analyses were used to assess horizontal pleiotropy. All statistical analyses were performed in R software. We discovered that Alloprevotella (IVW OR 0.84, 95% CI 0.71–0.99, P = .04) and Christensenellaceae R 7 group (IVW OR 0.71, 95% CI 0.52–0.99, P = .04) were negatively correlated with seropositive RA, Ruminococcaceae UCG002 (IVW OR 1.30, 95% CI 1.10–1.54, P = .002) was positively associated with seropositive RA. Actinomyces (IVW OR 0.73, 95% CI 0.54–0.99, P = .04), Christensenellaceae R 7 group (IVW OR 0.62, 95% CI 0.39–0.97, P = .04), Terrisporobacter (IVW OR 0.64, 95% CI 0.44–0.93, P = .02), Lactobacillales (IVW OR 0.65, 95% CI 0.47–0.90, P = .01) were negatively correlated with seronegative RA. The present MR analysis showed a protective effect of Alloprevotella and Christensenellaceae R 7 group and a potentially anti-protective effect of Ruminococcaceae UCG002 on seropositive RA; and a protective effect of Actinomyces, Christensenellaceae R 7 group, Terrisporobacter, and Lactobacillales on seronegative RA. Further experimental studies and randomized controlled trials are needed to validate these findings.

25 May 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
PJPing Jiang
Ping Jiang
KWKai Wei
Kai Wei
JZJianan Zhao
Jianan Zhao
YJYehua Jin
Yehua Jin
CCcen chang
cen chang
DHDongyi He
Dongyi He
Rheumatoid arthritis (RA) is a chronic, systemic, abnormal inflammatory immune response. It is characterized by the involvement of the synovium and multiple organs and the destruction of joints and articular cartilage. Over the past 30 years, several promising novel compounds and antibodies have been developed for the treatment of RA. The introduction of new drugs and precision medicine for all forms of RA raises several issues related to access to novel treatments by patients, optimal regimen selection, cost-effectiveness, prognosis monitoring and outcome surveillance, particularly with regarding to the development of low drug response rates, drug resistance and adverse side effects. Tremendous attention has been given to the identification of optimized drug combinations for the treatment of RA, particularly in early high-risk vulnerable and early individuals. Addressing these issues requires novel therapeutic approaches with new mechanisms and the establishment of accurate guidelines for drug selection, drug recombination, and non-chemical therapeutic efforts. In this study, we reviewed the most exciting recently established or ongoing novel drugs and methods according to the clinical trial database maintained by the United States National Library of Medicine and discussed the trends in RA drug development and challenges in the treatment, providing a reference significant for the accurate treatment of RA and the research direction in the future.

22 April 2020 in Preprints.org
Verified
Preprint
Open access
PDF file
Shicheng GuoShicheng Guo
Shicheng Guo
CCcen chang
cen chang
LXLingxia Xu
Lingxia Xu
RZRunrun Zhang
Runrun Zhang
YJYehua Jin
Yehua Jin
DHDongyi He
Dongyi He
MicroRNAs (miRNAs) play crucial roles in the regulation of the transcriptome and development of diseases including cancer and autoimmune diseases, such as rheumatoid arthritis (RA). Currently, a comprehensive map, illustrating how miRNAs regulate transcripts, pathways, immune system differentiation, and their interaction with terminal cells, such as T cells, fibroblast-like synoviocytes (FLS), osteoblasts, and osteoclasts, is still missing. In this review, we provide a thorough summary of the roles of miRNAs in the susceptibility to pathogenesis, diagnosis, therapeutic intervention, and prognosis of RA. Numerous miRNAs are abnormally expressed in cells involved in RA, and regulate target genes and pathways including the NF-κB, Fas-FasL, JAK-STAT, IRE1-RIDD, and mTOR pathways. By regulating gene expression, miRNAs affect T cell differentiation to diverse cell types, including Th17 and T-reg cells, and thus constitute promising gene therapy targets to modulate the immune system in RA. We summarize the diagnostic and prognostic potential of blood-circulating and cell-free miRNAs, highlighting the novel opportunities to combine these with rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) to provide accurate diagnosis and prognosis, especially for seronegative patients. Furthermore, we outline how functional genetic variants of miR-499 and miR-146a partly explain the unmet susceptibility to RA. Additionally, we review the evidence implicating miRNAs as promising biomarkers of efficiency, response, and resistance to disease-modifying anti-rheumatic drugs (DMRDs) and immunotherapy. Finally, we discuss the autotherapeutic effect of miRNA intervention as a step toward the development of miRNA-based anti-RA drugs. Collectively, the current evidence supports miRNAs as interesting targets to better understand the pathogenetic mechanisms of RA and design more efficient therapeutic interventions.

13 May 2021 in Research Square
Verified
Preprint
Open access
PDF file
RZRunrun Zhang
Runrun Zhang
YJYehua Jin
Yehua Jin
CCcen chang
cen chang
XZXinpeng Zhou
Xinpeng Zhou
YBYanqin Bian
Yanqin Bian
DHDongyi He
Dongyi He
Objective: This study identified to provide a comprehensive understanding of genome-wide expression patterns of synovial tissue from rheumatoid arthritis (RA) patients to investigate the potential mechanism RA occurrence and development. Methods: The transcription profiles of 9 RA and 15 control (osteoarthritis OA) synovial tissue were generated by RNA-Seq. Gene set enrichment analysis (GSEA) was used to analyze all detected genes and differentially expressed genes (DEGs) were identified by DESeq. To further analyze the DEGs, Gene ontology (GO) functional enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed. The protein-protein interaction (PPI) network of DEGs were constructed by STRING and the hub genes were identified by topology clustering with MCODE-Cytoscape. The most important hub genes were validated by quantitative real time polymerase chain reaction (qRT-PCR). Results: A total of 17736 genes were detected and 651 DEGs were identified. For the GSEA, significantly enriched gene sets positively correlated with the RA group were CD40 signaling over-activation, Th1 cytotoxic module in C2, over-activation of immune response, adaptive immune response in C5, In C7, the up-regulation of the gene set of effective versus memory CD8 T cell is related to RA group. The down-regulation of gene set of naïve versus effective CD8 T cell is related to RA group.in C7. Biology process enrichment analysis showed that the DEGs were significantly enriched for signal transduction (P=1.52×10-08), immune response (P=1.94×10-22) and inflammatory response (P=1.11×10-11). Molecule function enrichment analysis revealed over-represented calcium ion binding (P=8.61×10-03), receptor binding (P=7.03×10-05) and chemokine activity (P=4.15×10-15). The DEGs were significantly enriched for plasma membrane (P=2.26×10-20), integral component of membrane (P=7.79×10-07), extracellular region (P=3.43×10-16) in cellular component. The KEGG pathway analysis showed that the DEGs were enriched in the cytokine-cytokine receptor interaction (P=6.86×10-21), chemokine signaling pathway (P=2.03×10-11), systemic lupus erythematosus(P=9.23×10-07), T cell receptor signaling pathway (P=6.59×10-06) and rheumatoid arthritis (P=3.24×10-05). We confirmed RA over-expressed PPI network hub genes included CXCL13, CXCL6, CCR5, CXCR5, CCR2, CXCL3, CXCL10 and RA down-regulated hub genes included SSTR1. Conclusions: The study identified and verified the DEGs between RA and OA synovial tissue which highlighted the activity of a subset of chemokine genes, thereby providing novel insights into the molecular mechanisms of RA pathogenesis and identified potential diagnostic and therapeutic targets for RA.

15 April 2020 in Preprints.org
Verified
Preprint
Open access
PDF file
LXLingxia Xu
Lingxia Xu
Shicheng GuoShicheng Guo
Shicheng Guo
CCcen chang
cen chang
RZRunrun Zhang
Runrun Zhang
YJYehua Jin
Yehua Jin
DHDongyi He
Dongyi He
Rheumatoid arthritis (RA) as a complex disease is thought triggered by interaction between genetics and environment, especially the shared epitope (SE) and cell surface calreticulin (CSC) theory. However, all the evidence shows genetic diversity and environment exposure cannot explain all the clinical characteristics heterogeneity of rheumatoid arthritis. In contrast, recent studies demonstrate that epigenetics play important roles in the pathogenesis of rheumatoid arthritis, especially DNA methylation and histone modification. DNA methylation and histone methylation are involved in innate and adoptive immune cell differentiation and the migration, proliferation, apoptosis, and mesenchymal characteristics of fibroblast-like synoviocytes (FLS). Epigenetic mediated regulation to immune genes and inflammation pathway provides well explanation to dynamic expression network of rheumatoid arthritis. In this review, we summarized the comprehensive evidence to show methylation modification occurred in DNA and histone are significantly involved in the pathogenesis of rheumatoid arthritis and could be applied as the promising biomarker in the disease activity and drug response prediction. We also explained the opportunity and challenge of the current epigenetics research in rheumatoid arthritis. In summary, epigenetic modules provide possible interface through which genetic and environmental risk factors connect together to contribute to the susceptibility and pathogenesis of RA. Meanwhile epigenetic regulators provided promising drug targets to develop novel therapeutic drugs for rheumatoid arthritis. Finally, DNA methylation and histone modification will be important features to provide better rheumatoid arthritis subtype identification to accelerate personalized treatment and precision medicine.